Mikhail Kalinichev

Dr. Mikhail Kalinichev is Head of Translational Science and a member of the executive leadership team at Neurosterix (Geneva, Switzerland), a spinoff company from Addex Therapeutics. At Addex, he previously held senior leadership roles, including Head of Translational Science (2021–2024) and Associate Director and Group Leader in Behavioral Neuroscience (2009–2013).
Prior to rejoining Addex, Dr. Kalinichev served for six years as Director of In Vivo Neurology at Ipsen (France), where he contributed to the development of the neuroscience therapeutic strategy, led in vivo research activities, and initiated multiple industrial and academic collaborations in neuromuscular disorders and pain. Earlier in his career, he was Section Head at Lundbeck (Denmark), supporting translational research in schizophrenia, cognitive impairment, and pain, and a Principal Scientist at the Psychiatry Center of Excellence at GlaxoSmithKline (UK).
Dr. Kalinichev completed his postdoctoral training at the Department of Pharmacology, Emory University School of Medicine (USA), and earned a PhD in Behavioral Neuroscience from Rutgers University (USA). He is the recipient of several prestigious awards, including the Vernalis Prize from the British Association for Psychopharmacology and the GlaxoSmithKline Exceptional Science Award. He is an inventor on multiple patents and has co-authored over 60 peer-reviewed publications.